Table 3.

Risk of incident polyp by type in patients with IBD [n = 41 880] and matched general population comparators [n = 41 880], UC [n = 29 030] and matched general population comparators [n = 29 030], and CD [n = 12 850] and matched general population comparators [n = 12 850].

Group	IBD					UC					CD
	N events [%]		Incidence rate [95% CI] per 10 000 person-years		aHRa [95% CI]	No. of events [%]		Incidence rate [95% CI] per 10 000 person-years		aHRa [95%CI]	No. of events [%]		Incidence rate [95% CI] per 10 000 person years		aHRa [95% CI]
	IBD	Ref	IBD	Ref		UC	Ref	UC	Ref		CD	Ref	CD	Ref
Any polyp	1648 [3.9%]	1143 [2.7%]	46.1 [43.9–48.3]	34.2 [32.2–36.2]	1.23 [1.12–1.35]	1241 [4.3%]	820 [2.8%]	50.9 [48.1–53.7]	35.6 [33.1–38.0]	1.31 [1.17–1.46]	407 [3.2%]	323 [2.5%]	35.7 [32.3–39.2]	31.2 [27.8–34.6]	1.06 [0.89–1.27]
Tubular adenoma	1241 [3.0%]	885 [2.1%]	34.5 [32.6–36.4]	26.4 [24.6–28.1]	1.19 [1.06–1.33]	926 [3.2%]	633 [2.2%]	37.7 [35.3–40.2]	27.3 [25.2–29.5]	1.25 [1.09–1.42]	315 [2.5%]	252 [2.0%]	27.5 [24.5–30.6]	24.2 [21.3–27.2]	1.06 [0.86–1.30]
Sessile serrated polyps	16 [0.0%]	4 [0.0%]	0.4 [0.2–0.6]	0.1 [0.0–0.2]	8.50 [1.10–65.90]	12 [0.0%]	3 [0.0%]	0.5 [0.2–0.7]	0.1 [–0.0–0.3]	6.13 [0.63–59.66]	4 [0.0%]	1 [0.0%]	0.3 [0.0–0.7]	0.1 [−0.1 to 0.3]	—
Polyp unspecified with LGD	40 [0.1%]	12 [0.0%]	1.1 [0.8–1.4]	0.4 [0.2–0.6]	2.09 [0.97–4.49]	35 [0.1%]	12 [0.0%]	1.4 [0.9–1.9]	0.5 [0.2–0.8]	1.67 [0.75–3.71]	5 [0.0%]	0	0.4 [0.1–0.8]	0.0 [0.0–0.0]	—
Any advanced polyp	544 [1.3%]	381 [0.9%]	14.9 [13.7–16.2]	11.2 [10.1–12.4]	1.18 [1.00–1.39]	428 [1.5%]	269 [0.9%]	17.2 [15.6–18.9]	11.5 [10.1–12.9]	1.38 [1.13–1.68]	116 [0.9%]	112 [0.9%]	10.0 [8.2–11.9]	10.7 [8.7–12.7]	0.79 [0.57–1.09]
Sessile serrated poyps with LGD	8 [0.0%]	3 [0.0%]	0.2 [0.1–0.4]	0.1 [–0.0–0.2]	8.27 [0.59–116.09]	7 [0.0%]	2 [0.0%]	0.3 [0.1–0.5]	0.1 [–0.0–0.2]	8.73 [0.46–166.97]	1 [0.0%]	1 [0.0%]	0.1 [−0.1 to 0.3]	0.1 [−0.1 to 0.3]	—
Sessile serrated polyps with HGD	0	0	0.0 [0.0–0.0]	0.0 [0.0–0.0]	—	0	0	0.0 [0.0–0.0]	0.0 [0.0–0.0]	–	0	0	0.0 [0.0–0.0]	0.0 [0.0–0.0]	—
Traditional serrated adenomas	74 [0.2%]	37 [0.1%]	2.0 [1.6–2.5]	1.1 [0.7–1.4]	1.72 [1.02–2.91]	58 [0.2%]	23 [0.1%]	2.3 [1.7–2.9]	1.0 [0.6–1.4]	2.64 [1.34–5.19]	16 [0.1%]	14 [0.1%]	1.4 [0.7–2.1]	1.3 [0.6–2.0]	0.76 [0.31–1.86]
Traditional serrated adenomas with LGD	23 [0.1%]	12 [0.0%]	0.6 [0.4–0.9]	0.4 [0.2–0.6]	1.76 [0.69–4.50]	17 [0.1%]	8 [0.0%]	0.7 [0.4–1.0]	0.3 [0.1–0.6]	2.35 [0.74–7.52]	6 [0.0%]	4 [0.0%]	0.5 [0.1–0.9]	0.4 [0.0–0.8]	0.84 [0.13–5.60]
Traditional serrated adenomas with HGD	0	0	0.0 [0.0–0.0]	0.0 [0.0–0.0]	—	0	0	0.0 [0.0–0.0]	0.0 [0.0–0.0]	—	0	0	0.0 [0.0–0.0]	0.0 [0.0–0.0]	—
Tubulovillous	437 [1.0%]	315 [0.8%]	12.0 [10.9–13.1]	9.3 [8.3–10.3]	1.13 [0.94–1.36]	341 [1.2%]	226 [0.8%]	13.7 [12.2–15.2]	9.6 [8.4–10.9]	1.28 [1.03–1.58]	96 [0.7%]	89 [0.7%]	8.3 [6.6–10.0]	8.5 [6.7–10.3]	0.82 [0.58–1.17]
Tubulovillous with HGD	24 [0.1%]	20 [0.0%]	0.7 [0.4–0.9]	0.6 [0.3–0.8]	1.66 [0.75–3.70]	19 [0.1%]	16 [0.1%]	0.8 [0.4–1.1]	0.7 [0.3–1.0]	1.93 [0.75–4.95]	5 [0.0%]	4 [0.0%]	0.4 [0.1–0.8]	0.4 [0.0–0.8]	1.05 [0.21–5.28]
Villous	35 [0.1%]	28 [0.1%]	1.0 [0.6–1.3]	0.8 [0.5–1.1]	1.41 [0.71–2.81]	30 [0.1%]	17 [0.1%]	1.2 [0.8–1.6]	0.7 [0.4–1.1]	2.15 [0.89–5.16]	5 [0.0%]	11 [0.1%]	0.4 [0.1–0.8]	1.0 [0.4–1.7]	0.67 [0.19–2.36]
Villous with HGD	3 [0.0%]	1 [0.0%]	0.1 [–0.0–0.2]	0.0 [−0.0 to 0.1]	—	0	0	0.0 [0.0–0.0]	0.0 [0.0–0.0]	—	3 [0.0%]	1 [0.0%]	0.3 [−0.0 to 0.6]	0.1 [−0.1 to 0.3]	—
Tubulous with HGD	21 [0.1%]	25 [0.1%]	0.6 [0.3–0.8]	0.7 [0.4–1.0]	0.54 [0.22–1.33]	19 [0.1%]	21 [0.1%]	0.8 [0.4–1.1]	0.9 [0.5–1.3]	0.68 [0.26–1.80]	2 [0.0%]	4 [0.0%]	0.2 [−0.1 to 0.4]	0.4 [0.0–0.8]	0.00 [0.00–.]
Polyp unspecified with HGD	3 [0.0%]	0	0.1 [–0.0–0.2]	0.0 [0.0–0.0]	—	3 [0.0%]	0	0.1 [−0.0 to 0.3]	0.0 [0.0–0.0]	–	0	0	0.0 [0.0–0.0]	0.0 [0.0–0.0]	—

^aAdjusted for age, sex, calendar period, and number of endoscopies at baseline.